EZH2 is an epigenetic enzyme that controls how genes are silenced by modifying chromatin. For years it was viewed mainly as a cancer target to be blocked. But new thinking shows that both too little and too much EZH2 activity drives aging-related tissue breakdown, depending on the tissue type. This review, published in Biogerontology, surveys natural compounds that may gently tune EZH2 activity rather than shutting it down entirely. The authors argue that heavy-handed pharmaceutical inhibition risks destabilizing chromatin in healthy tissues, while carefully chosen natural modulators could restore epigenetic balance. The work points toward a new class of plant-derived and dietary compounds as candidate geroprotective agents targeting aging at the epigenetic level — a promising but still early-stage frontier.
